関連する実験動画

Updated: Feb 13, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

ULK1/2キナーゼ阻害剤の合成と特徴化,これは,非小細胞肺がんの治療のために,オートファギーを阻害し,メジャー・ヒストコンパティビリティ・コンプレックスIのプレグラート発現を阻害する

Fabiana Izidro A L Layng¹, Huiyu Ren¹, Nicole A Bakas¹

¹Center for Therapeutics Discovery, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, United States.

ACS chemical biology

|February 12, 2026

まとめ

新しい二重ULK1/2阻害剤SBP-5147およびSBP-7501は,非小細胞肺がん (NSCLC) の治療に有望であることが示されています. これらの化合物は細胞毒性であり,オートファギーを阻害し,経口曝露を改善し,免疫療法反応を潜在的に強化します.

科学分野:

腫瘍学腫瘍学
分子生物学は分子生物学である.
薬理学薬理学とは

背景:

オートファギーの抑制は,特に非小細胞肺がん (NSCLC) に対して,潜在的ながん治療法です.
以前の研究で,SBP-7455はunc-51-likeキナーゼ1 (ULK1) とULK2の二重阻害体として特定され,三重陰性乳がん (TNBC) に効果を示した.

研究の目的:

新型デュアルULK1/2阻害剤SBP-5147およびSBP-7501.1の設計,合成,および特徴づけを行う.
これらの新しい化合物のNSCLC細胞に対する有効性,およびオートファジックフルスに対するそれらの効果を評価する.
新しい阻害剤の薬理 Untuak manilai sifat farmakokinetik,および潜在的な免疫調節効果.

主な方法:

SBP-5147とSBP-7501の化学合成と特徴付けについて
NSCLCの細胞系における細胞毒性測定.
A549細胞におけるオートファージ流動抑制の評価.
経口曝露を決定する薬理学研究.
メジャー・ヒストコンパティビリティ・コンプレックス (MHC) クラスI発現の分析.

主要な成果:

SBP-5147およびSBP-7501は,NSCLC細胞に対する細胞毒性を実証しました.
この2つの化合物は,A549細胞における自滅性流動を抑制した.
SBP-5147とSBP-7501は,より低い用量でSBP-7455よりも高い経口被曝を示した.
SBP-5147は,NSCLC細胞における自己消化を調節し,MHCクラスI発現を増加させた.

結論:

SBP-5147とSBP-7501は,NSCLC治療の可能性のある有効な二重ULK1/2阻害剤です.
これらの化合物は,SBP-7455.5と比較して,改善された薬理学プロファイルを提供します.
ULK1/2の阻害は,MHCクラスIの発現を増加させることで免疫療法を強化し,耐性を克服する役割を示唆する可能性があります.
ULK阻害剤は,単独でも,がんの併用療法でも有効な治療戦略です.

さらに関連する動画

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Stability and Structure of Bat Major Histocompatibility Complex Class I with Heterologous β2-Microglobulin

Stability and Structure of Bat Major Histocompatibility Complex Class I with Heterologous β2-Microglobulin

Published on: March 10, 2021

関連する概念動画

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Eukaryotic Transcription Inhibitors

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...

Protein Kinases and Phosphatases

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

What is Gene Expression?

What is Gene Expression?

Overview
Gene expression is the process in which DNA directs the synthesis of functional products, that is, proteins. Cells can regulate gene expression at various stages. It allows organisms to generate different cell types and enables cells to adapt to internal and external factors.
Genetic Information Flows from DNA to RNA to Protein
A gene is a stretch of DNA that serves as the blueprint for functional RNAs and proteins. Since DNA is made up of nucleotides and proteins consist of amino...